Plasma endocan level and prognosis of immunoglobulin A nephropathy

• Published in: Kidney research and clinical practice 2016, 35(3), , pp.152-159
• Main Authors: Lee, Yu Ho, Kim, Jin Sug, Kim, Se-Yun, Kim, Yang Gyun, Moon, Ju-Young, Jeong, Kyung-Hwan, Lee, Tae Won, Ihm, Chun-Gyoo, Lee, Sang-Ho
• Format: Article
• Language: English
• Subjects: Endocan; Endothelial cell–specific molecule-1; Immunoglobulin A nephropathy; Original; 내과학
• ISSN: 2211-9132; 2211-9140
• DOI: 10.1016/j.krcp.2016.07.001

Endocan, previously called endothelial cell–specific molecule-1, is a soluble proteoglycan that is secreted from vascular endothelial cells. Elevated plasma endocan levels were shown to be associated with poor cardiovascular outcomes in patients with chronic kidney disease (CKD). We investigated the clinical relevance of plasma and urine endocan levels in patients with immunoglobulin A nephropathy (IgAN). Sixty-four patients with IgAN and 20 healthy controls were enrolled in this study. Plasma and urine endocan levels were measured. Clinical parameters, pathologic grades, and renal outcomes were compared among subgroups with different plasma and urine endocan levels. Both plasma and urine endocan levels were significantly higher in patients with IgAN than in controls. Elevated serum phosphorus and C-reactive protein were independent determinants for plasma endocan, and elevated C-reactive protein was also an independent determinant for urine endocan levels in multivariate analysis. Plasma endocan level was not significantly different across CKD stages, but patients with higher plasma endocan levels showed adverse renal outcome. Urine endocan levels were also elevated in patients with poor renal function. Cox proportional hazard models showed that high plasma endocan was an independent risk factor for CKD progression after adjusting for the well-known predictors of outcome in patients with IgAN. This study suggested that plasma endocan might be useful as a prognostic factor in patients with IgAN.